Cardiotoxicity of cancer chemotherapy in clinical practice

References

• Siegel RL, Miller KD, Jemel A. Cancer statistics 2018. CA. Cancer J Clin. 2018;68:7–30. PMID:29313949.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemel A. Cancer statistics 2017. CA Cancer J Clin. 2017;67:7–30. PMID: 28055103.
   PubMed Web of Science ®Google Scholar
• Skitch A, Mital S, Mertens L, et al. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer. 2017;17:519. PMID: 28774277.
   PubMed Web of Science ®Google Scholar
• Zheng HC, Onderko L, Sa F. Cardiovascular risk in survivors of cancer. Curr Cardiol Rep. 2017;19:64. PMID: 28550591.
   PubMed Web of Science ®Google Scholar
• Russell RR, Alexander J, Jain D, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23:856–884.
   PubMed Web of Science ®Google Scholar
• Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol. 2013;20:443–464.
   PubMed Web of Science ®Google Scholar
• Jain D, Russell RR, Schwartz RG, et al. Cardiac complications of cancer therapy: pathophysiology, identification, prevention and treatment and future directions. Curr Cardiol Rep. 2017;19:36. PMID: 28374177.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Jour Clin Invest. 2014;124:617–630.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–1988.
   PubMed Web of Science ®Google Scholar
• Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68:261–271.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642.
   PubMed Web of Science ®Google Scholar
• Panjrath GS, Patel V, Valdiviezo CI, et al. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol. 2007;49:2457–2464.
   PubMed Web of Science ®Google Scholar
• Lien CY, Jensen BT, Hydock DS, et al. Short-term exercise training attenuates acute doxorubicin cardiotoxicity. J Physiol Biochem. 2015;71:669–678. PMID: 26403766.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insight based upon clinical course and response to medical treatment. J Cli Oncol. 2005;23:7820–7826.
   PubMed Web of Science ®Google Scholar
• Miranda CJ, Makui H, Soares RJ, et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood. 2003;102:2574–2580.
   PubMed Web of Science ®Google Scholar
• Choi BW, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J. 1983;106:638–643.
   PubMed Web of Science ®Google Scholar
• Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10:132–139.
   PubMed Web of Science ®Google Scholar
• Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109–1118.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77–84.
   PubMed Web of Science ®Google Scholar
• Khouri MG, Ky B, Dunn G, et al. Echocardiography core laboratory reproducibility of cardiac safety assessments in cardio-oncology. J Am Soc Echocardiogr. 2018;31:361–371e3. pii: S0894-7317(17)30826-X. pii: S0894-7317(17)30826-X.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62–69.
   PubMed Web of Science ®Google Scholar
• Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol. 2013;61:85–87.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63:2751–2768.
   PubMed Web of Science ®Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of echocardiography and the European Association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–1093.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911.
   PubMed Web of Science ®Google Scholar
• Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18:930–936.
   PubMed Web of Science ®Google Scholar
• Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circulation Cardiovascular Imaging. 2012;5:596–603.
   PubMed Web of Science ®Google Scholar
• de Vries Schultink AHM, Boekhout AH, Gietema JA, et al. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. J Pharmacokinet Pharmacodyn. 2018 Feb 10. [Epub ahead of print] . PMID: 29429038. DOI:10.1007/s10928-018-9579-8.
   PubMed Web of Science ®Google Scholar
• Quatromoni N, Scherrer-Crosbie M. Update on incorporating biomarkers with imaging findings for the detection and management of cardiotoxicity. Curr Cardiol Rep. 2018;20:67. Review. PMID: 29931487.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–1988. PMID: 25948538. .
   PubMed Web of Science ®Google Scholar
• Children’s oncology group long-term follow up guidelines for survivors of childhood, adolescent and young adult cancer (version 4, Oct 2013). p 25–26. [cited 2018 Sep 01]. www.survivorshipguidelines.org/pdf/COG_LTFU_Guidelines_Appendix1_v4.pdf.
   Google Scholar
• Feijen EA, Leisenring WM, Stratton KL, et al. Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. J Clin Oncol. 2015;33:3774–3780. PMID: 26304888.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–220.
   PubMed Web of Science ®Google Scholar
• Nabati M, Janbabai G, Baghyari S, et al. Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol. 2017;69:279–285. PMID: 28141699.
   PubMed Web of Science ®Google Scholar
• Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71:2281–2290. PMID: 29540327.
   PubMed Web of Science ®Google Scholar
• Galderisi M, Sorrentino R, Esposito R. Can carvedilol prevent chemotherapy-related cardiotoxicity?: a dream to be balanced with tolerability. J Am Coll Cardiol. 2018;72:1181–1182. PMID: 30165996. .
   PubMed Web of Science ®Google Scholar
• Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493–500.
   PubMed Web of Science ®Google Scholar
• Leung HWC, Leung JH, Chan ALF. Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis. Expert Opin Drug Saf. 2018;17:1–7. PMID: 29108432. .
   PubMed Web of Science ®Google Scholar
• Kurokawa YK, Shang MR, Yin RT, et al. Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Toxicol Lett. 2018:pii: S0378-4274(18)30001–8 PMID: 29305325. Doi:10.1016/j.toxlet.2018.01.001.
   PubMed Web of Science ®Google Scholar
• Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007;28:69–73.
   PubMed Web of Science ®Google Scholar
• Foldi J, Mougalian S, Silber A, et al. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Breast Cancer Res Treat. 2018 Feb 2. PMID: 29396664. DOI:10.1007/s10549-017-4653-2.
   PubMed Web of Science ®Google Scholar
• Masuda N, Toi M, Yamamoto N, et al. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer. 2018 Feb 14. [Epub ahead of print] PMID: 29445928. DOI:10.1007/s12282-018-0839-7.
   Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al.; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–734. PMID:25693012. .
   PubMed Web of Science ®Google Scholar
• Herold K. Overview of the CLEOPATRA trial: implications for advanced practitioners. J Adv Pract Oncol. 2016;7: 83–89. Review. PMID: 27713847.
   PubMedGoogle Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. APHINITY steering committee and investigators. adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–131. Erratum in: N Engl J Med. 2017 17;377:702.PMID: 28581356. .
   PubMed Web of Science ®Google Scholar
• Giordano SH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;JCO2018792697. DOI:10.1200/JCO.2018.79.2697
   Google Scholar
• Hassan SA, Palaskas N, Kim P, et al. Chemotherapeutic agents and the risk of ischemia and arterial thrombosis. Curr Atheroscler Rep. 2018;20:10. PMID: 29423705.
   PubMed Web of Science ®Google Scholar
• Kwakman JJM, Baars A, van Zweeden AA, et al. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. Eur J Cancer. 2017;81:130–134. PMID: 28623776. .
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8:191–202.
   PubMed Web of Science ®Google Scholar
• Polk A, Vistisen K, Vaage-Nilsen M, et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47.
   PubMed Web of Science ®Google Scholar
• Florian S, Mitchison TJ. Anti-microtubule drugs. Methods Mol Biol. 2016;1413:403–421. PMID: 27193863. .
   PubMedGoogle Scholar
• Ward S, Simpson E, Davis S, et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11: 1–144. PMID: 17903394.
   Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, et al. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37: 1590–1598. Review. PMID: 11527683.
   PubMed Web of Science ®Google Scholar
• Blair HA, Deeks ED. Albumin-bound paclitaxel: a review in non-small cell lung cancer. Drugs. 2015;75:2017–2024. PMID: 26541764. .
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a new generation taxane. Exp Opinion Pharmacol. 2006;8:1041–1053.
   Google Scholar
• McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncology: Journal Eur Soc Ther Radiol Oncol. 2011;100:167–175.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998.
   PubMed Web of Science ®Google Scholar
• Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25:3031–3037.
   PubMed Web of Science ®Google Scholar
• Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol. 2012;30:380–386.
   PubMed Web of Science ®Google Scholar
• Yang B, Papoian T. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: past, present and future. J Appl Toxicol. 2018 Jan 25. [Epub ahead of print]. PMID: 29369373. DOI:10.1002/jat.3584.
   Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212.
   PubMed Web of Science ®Google Scholar
• Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53:114–120. PMID: 20728698. .
   PubMed Web of Science ®Google Scholar
• Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5:187ra69.
   PubMed Web of Science ®Google Scholar
• Ophranos GS, Ionnidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica. 2009;48:964–970.
   PubMed Web of Science ®Google Scholar
• León-Mateos L, Mosquera J. Antón aparicio L treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol. 2015;6:421–425.
   PubMed Web of Science ®Google Scholar
• Akinijiyan FA, Carbonneau S, Ross NT. Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system. Bioorganic Med Chem Lett. 2017;17:4589–4696.
   Google Scholar
• Salami J, Crews CM. Waste disposal-An attractive strategy for cancer therapy. Science. 2017;355:1163–1167. Review. PMID: 28302825. .
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Reece DE, Trudel S, et al. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leuk Lymphoma. 2015;56:232–235.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2017 Dec 28. [Epub ahead of print]. [Epub ahead of print]. Doi:10.1001/jamaoncol.2017.4519.
   Web of Science ®Google Scholar
• Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16:11–20.
   PubMed Web of Science ®Google Scholar
• Wolchok JDPD-1. blockers. Cell. 2015;162:93.
   Web of Science ®Google Scholar
• Postov MA, Sidlow R, Hellmann MD. Immune related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–169.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee HT, Shin W, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7:13354.
   PubMed Web of Science ®Google Scholar
• Khoja LDD, Wei-Wu Chen T, Siu LL, et al. Tumour and class specific patterns of immune-related advese events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377–2385.
   PubMed Web of Science ®Google Scholar
• Yu C, Chopra IJ, Ha E. A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep. 2015;2015:140092.
   PubMedGoogle Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combined checkpoint inhibitors. N Engl J Med. 2016;375:1749–1755.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457–1467.
   PubMed Web of Science ®Google Scholar